SCHEMBL6206980

SCHEMBL6206980

Nc1cc2c(cc1Cl)CCC2=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50
HSD17B10 Q99714 1/20 0.50
GAA P10253 1/20 0.42
PBRM1 Q86U86 1/20 0.41
TYMS P04818 2/20 0.40
HSD17B1 P14061 2/20 0.37
PTGS1 P23219 3/20 0.35
PTGS2 P35354 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
PRKCI P41743 1/20 0.35
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
GRM5 P41594 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.33
SRD5A1 P18405 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1512735 0.83 PBRM1 (0.47) CASP1CASP7HSD17B10PBRM1TYMS
SCHEMBL31591225 0.83 PBRM1 (0.47) CASP1CASP7HSD17B10PBRM1TYMS
SCHEMBL460543 0.83 CASP1 (0.57) CASP1CASP7HSD17B10PBRM1TYMS
SCHEMBL31511760 0.76 PBRM1 (0.41) CASP1CASP7HSD17B10PBRM1TYMS
SCHEMBL21962019 0.76 PBRM1 (0.41) CASP1CASP7HSD17B10PBRM1TYMS
SCHEMBL2300153 0.76 CASP7 (0.50) CASP1CASP7HSD17B10PBRM1TYMS
SCHEMBL29618363 0.76 CASP7 (0.50) CASP1CASP7HSD17B10PBRM1TYMS
SCHEMBL2907226 0.76 PBRM1 (0.41) CASP1CASP7HSD17B10PBRM1TYMS
SCHEMBL7888335 0.76 CASP1 (0.50) CASP1CASP7HSD17B10PBRM1HSD17B1
SCHEMBL1025098 0.76 HSD17B10 (0.50) CASP1CASP7HSD17B10PBRM1TYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109956928-B Pyridine compound, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2021-07-09 CN disclosed
EP-1603887-B1 HIV REPLICATION INHIBITING INDANE SUBSTITUTED PYRIMIDINES TIBOTEC PHARM LTD (IE) 2011-04-20 EP disclosed
US-7585870-B2 HIV replication inhibiting pyrimidines and triazines TIBOTEC BVBA (BE) 2009-09-08 US disclosed
US-7585870-B2 HIV replication inhibiting pyrimidines and triazines TIBOTEC BVBA (BE) 2009-09-08 US disclosed
US-7442705-B2 HIV replication inhibiting pyrimidines and triazines TIBOTEC PHARMACEUTICALS LTD (IE) 2008-10-28 US disclosed
US-7442705-B2 HIV replication inhibiting pyrimidines and triazines TIBOTEC PHARMACEUTICALS LTD (IE) 2008-10-28 US disclosed
EP-1597238-B1 HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES TIBOTEC PHARM LTD (IE) 2007-05-09 EP disclosed
EP-1098891-B1 POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS AVENTIS PHARMA GMBH (DE) 2005-08-10 EP disclosed
EP-1098891-A1 POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS Aventis Pharma Deutschland GmbH (DE) 2001-05-16 EP disclosed
US-6159996-A Polycyclic thiazolidin-2-ylidene amines, process for their preparation, and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-12-12 US disclosed
WO-2000004006-A1 POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-01-27 WO disclosed
US-4129656-A Thiazolidine derivatives, salidiuretic compositions and methods of effecting salidiuresis employing them HOECHST AKTIENGESELLSCHAFT (DE) 1978-12-12 US disclosed